Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250

Benzinga Newsdesk www.benzinga.com Positive 81.3%

Neg 0% Neu 0% Pos 81.3%

Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $230 to $250.